MOLECULAR PARTNERS ADS/1 (6ML0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has a cash flow conversion efficiency ratio of -0.139x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.15 Million ≈ $-13.04 Million USD) by net assets (€80.33 Million ≈ $93.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 6ML0 equity to assets ratio to measure how much of total assets are equity-financed.
MOLECULAR PARTNERS ADS/1 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how MOLECULAR PARTNERS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of MOLECULAR PARTNERS ADS/1 to evaluate the quality of earnings relative to operating cash generation.
MOLECULAR PARTNERS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ANDHRA PAPER LIMITED
NSE:ANDHRAPAP
|
0.033x |
|
Midas Minerals Ltd
AU:MM1
|
-0.189x |
|
Innate Pharma
NASDAQ:IPHA
|
1.078x |
|
Motorcycle Holdings Ltd
AU:MTO
|
0.121x |
|
American Well Corp
NYSE:AMWL
|
-0.004x |
|
Avadh Sugar & Energy Limited
NSE:AVADHSUGAR
|
0.864x |
|
Sif Holding NV
AS:SIFG
|
0.147x |
|
Takarék Jelzálogbank Nyrt
F:FH21
|
-0.130x |
Annual Cash Flow Conversion Efficiency for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of MOLECULAR PARTNERS ADS/1 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see MOLECULAR PARTNERS ADS/1 (6ML0) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €80.33 Million ≈ $93.92 Million |
€-51.26 Million ≈ $-59.92 Million |
-0.638x | -52.53% |
| 2024-12-31 | €141.64 Million ≈ $165.59 Million |
€-59.25 Million ≈ $-69.27 Million |
-0.418x | -25.08% |
| 2023-12-31 | €176.43 Million ≈ $206.26 Million |
€-59.01 Million ≈ $-68.98 Million |
-0.334x | -166.33% |
| 2022-12-31 | €235.17 Million ≈ $274.93 Million |
€118.57 Million ≈ $138.62 Million |
0.504x | +159.47% |
| 2021-12-31 | €107.29 Million ≈ $125.43 Million |
€-90.95 Million ≈ $-106.33 Million |
-0.848x | -- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more